IMRE'S PROSORBA COLUMN TTP CLINICAL TRIAL
This article was originally published in The Gray Sheet
Executive Summary
IMRE'S PROSORBA COLUMN TTP CLINICAL TRIAL is set to begin following FDA investigational device exemption approval, announced by the company Jan. 18. The device will be evaluated for the treatment of thrombotic thrombocytopenic purpura, an autoimmune disease marked by low platelet count, destruction of red blood cells and kidney failure or neurological disorders.